Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
- Shionogi Introduces AI Chatbot for Xofluza Inquiries from Medical Professionals
December 3, 2019
- Satralizumab Reduces Risk of NMOSD Relapses: Chugai
December 2, 2019
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
- Boehringer Innovation Chief Touts R&D Efforts on Undruggable Cancer Targets
December 2, 2019
- Santen Starts Voluntary Recall of Pivalephrine
December 2, 2019
- Takeda Submits Niraparib for Ovarian Cancer in Japan
December 2, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
- Rick Kozloski Tapped as President of Alcon Japan
November 29, 2019
- Hisamitsu, Kyowa Kirin Put Off Launch of Haruropi Tape due to Faulty Barcode
November 29, 2019
- Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
- Ono Files Tirabrutinib for Add’l Indications in Japan
November 28, 2019
- Ono Seeks to Add 4-Week Dosing to Opdivo Monotherapy
November 28, 2019
- Chugai to End Joint Venture with South Korea's JW Pharma
November 28, 2019
- Chugai Launches Tecentriq 840 mg for Triple-Negative Breast Cancer
November 28, 2019
- ASKA’s Oral Hysteromyoma Drug Shows Non-Inferiority to Leuprorelin in PIII
November 28, 2019
- Sumitomo Dainippon to Launch Global Data Design Office, Leveraging Roivant’s Technology
November 28, 2019
- Otsuka Completes Construction of New Plant in Tokushima
November 28, 2019
- Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
November 27, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…